Prediction of overall survival (OS) prognosis for chromophobe renal cell carcinoma of post nephrectomy patients: A SEER database study

The aim of this study based on the Overall Survival prognosis of patients with Chromophobe Renal Cell Carcinoma (ChRCC) is to help Urology department doctors to improve their clinical approach on ChRCC by giving out a clear idea on the choice of treatment methods and prognosis of this particular cancer. This study included 3108 patients diagnosed with ChRCC from the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015. We collected data from a single center in China. In total, we selected from the period of 1st January 2010 to 31st December 2021, 225 patients diagnosed with ChRCC by the pathology department after nephrectomy was performed. Chromophobe Renal Cell Carcinoma was more found in younger and middle age patients (50.19% & 36.81% from SEER; 74.22%& 24% from china). Patients with bigger tumor size (>108mm) are more likely to have a worse OS rate (HR-1 = 0.229; P= 0.0194). American Joint Committee on Cancer (AJCC) TNM stages in our study showed that there was a worse survival rate interval in older patients with T3 or T4. The Cancer-Specific Survival rate in our research is over 98% since there are less than 2% patients with Sarcomatoid features or Regional positive lymph-nodes after nephrectomy. Chromophobe Renal Cell Carcinoma presents a favorable Overall Survival (OS) prognosis. Our study shows that significantly fewer patients present sarcomatoid features, which justifies the fact that ChRCC has a better Cancer-Specific Survival rate. However, those presenting sarcomatoid features with/without positive lymph-node have a poor prognosis. Although total nephrectomy remains the gold standard of treatment, we encourage that more future research should be done to develop a better oncological therapeutic treatment for those with metastasis.